Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for AGILE THERAPEUTICS INC.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Oct 2021, 16:05.
PERCEPTIVE ADVISORS LLC - 13 Oct 2021 Form 4 Insider Report for AGILE THERAPEUTICS INC
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 13 Oct 2021
- Net transaction value
- +$4,874,376
- SEC form
- 4
- Accepted by SEC
- 15 Oct 2021, 16:05:28 UTC
- Prior SEC filing
- 14 Oct 2021
- Next SEC filing
- 25 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for AGILE THERAPEUTICS INC on 15 Oct 2021.
Change
- Previous filing in this sequence was filed on 14 Oct 2021.
- Current net transaction value: +$4,874,376.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGRX
transaction
Common Stock
Purchase
- Transaction value
- $4,874,376
- Shares
- +5,734,560
- Change %
- +36%
- Price
- $0.8500
- Shares after
- 21,654,485
- Date
- 13 Oct 2021
- Ownership
- See footnote
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGRX
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +2,687,280
- Change %
- Price
- Shares after
- 2,687,280
- Date
- 13 Oct 2021
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,687,280
- Exercise price
- $0.8500
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities reported on this Form 4 were acquired as a unit, with each unit consisting of one share of common stock and one-half of a warrant to purchase one share of common stock, with a combined price of $0.85 per unit. The warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer???s outstanding shares of common stock following the exercise.
Footnote F2
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.